Business Wire

1. Cadent Therapeutics Announces FDA Acceptance Of IND Application For CAD-1883 For Spinocerebellar Ataxia (SCA) 1/23/2020

   Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial for CAD-1883, a novel, first-in-class, positive allosteric modulator (PAM) of SK channels (calcium-sensitive potassium ion channels) for the treatment of spinocerebellar ataxia (SCA)

2. PhoreMost Enters Multi-Project Drug Discovery Collaboration With Otsuka Pharmaceutical 1/21/2020

   PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project collaboration with Otsuka Pharmaceutical Co., the world-leading pharmaceutical company dedicated to the research and development of highly-innovative drugs and diagnostics

3. Charles River Laboratories And Fios Genomics Form A Strategic Alliance To Provide Bioinformatics-Driven Drug Discovery And Safety Assessment 1/16/2020

   Charles River Laboratories International, Inc. today announced that it has entered into an exclusive partnership with Fios Genomics, a leading provider of bioinformatics data analysis services. Access to high quality, transparent bioinformatics presents a challenge for many drug development teams

4. HitGen Enters Into DNA-Encoded Library Based Drug Discovery Research Collaboration With Kymera 1/14/2020

   HitGen Inc. today announced that it has entered into a drug discovery research collaboration with Kymera Therapeutics, Inc., to identify small molecule leads against targets of interest to Kymera

5. GNT Pharma's Anti-Dementia Drug 'Crisdesalazine' Demonstrates Efficacy In Phase III Clinical Study With Companion Dogs With Dementia 1/14/2020

   GNT Pharma has successfully completed a Phase III clinical trial for crisdesalazine, a new drug for treating canine cognitive dysfunction syndrome or Alzheimer’s disease

6. A2A Pharmaceuticals Inc. Today Announced A Multi-Target Co-Development Agreement With Daewoong Pharmaceutical For AI-Enhanced Oncology Drug Discovery 1/14/2020

   A2A Pharmaceuticals Inc. (A2A) announced an agreement to design and co-develop oncology drug candidates with Daewoong Pharmaceutical Co., Ltd. (Daewoong), a major pharmaceutical company in South Korea, using its proprietary AI-enabled drug discovery platform SCULPT

7. ZebiAI Therapeutics, Inc. Announces Collaboration With Google Accelerated Science To Focus On Unlocking Novel Therapeutic Targets And Transforming Small Molecule Drug Discovery 1/13/2020

   ZebiAI Therapeutics, Inc., a privately held company, announced a multiyear service and collaboration agreement with Google Accelerated Science (GAS) (https://research.google/teams/applied-science/gas/), Mountain View, CA, focused on the application of machine learning to accelerate the identification of small molecule therapeutics

8. Inflazome IP Portfolio Strengthened With Patents Granted In US And Europe 1/13/2020

   Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple small molecule drugs that block harmful inflammation, today announces that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) will grant the patent application WO 2016/131098 as US 10,538,487 on 21 January 2020 and EP 3,259,253 on 15 January 2020

9. PPD Expanding Clinical Development And Laboratory Capabilities In China 1/9/2020

   PPD, Inc. (PPD) has expanded its operations and leadership team in China to provide enhanced clinical development, laboratory, regulatory, site conduct, patient access and post-approval services for international and China-based biopharmaceutical companies

10. Evotec And Bayer Announce New Alliance Focusing On Drug Discovery For Polycystic Ovary Syndrome With Novel Targets From Celmatix 1/9/2020

    Evotec SE and Bayer AG today announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration with participation from Celmatix Inc. to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”)